arrow
返回
M

Martin R. Stockler

australia and new zealand urogenital and prostate cancer trials group

65H指数
631论文数
2.1W被引数
收录论文 144
发表时间
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial胰岛素样生长因子轴与转移性激素敏感型前列腺癌的生存:来自ENZAMET III期试验的事后分析
err2026-09-30
err0
errOAAI
errMichael A. Cilento; Hui-Ming Lin; Nicole Yeung; Rachel M.N. Kim; Neil Portman; Martin R. Stockler; Andrew J. Martin; Vinod Subhash; Sonia Yip; Lisa M. Butler; Ian C. Marschner; Peter J. Meikle; Arun A. Azad; Ian D. Davis; Lisa G. Horvath; Christopher J. Sweeney
err分享
err收藏
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial奥拉帕利在HR缺陷、转移性三阴性乳腺癌和铂敏感复发性卵巢癌中BRCA1/2无胚系突变患者中的疗效:EMBRACE二期临床试验
err2026-07-08
err0
errOAAI
errKatrin M. Sjoquist; Alexander Dobrovic; Kristy P. Robledo; Ksenija Nesic; Sally Baron-Hay; Sumitra Ananda; Nicole McCarthy; Jeffrey Goh; Christopher Steer; Nick Murray; Sonia Yip; Linda R. Mileshkin; J. Lynn Fink; Garry Chang; Lisa Bailey; Yvonne Lee; Danka S. Zebic; U. G. Imalki U. Kariyawasam; Kristy Shield-Artin; Andrew Jarratt; Justin Bedő; Anthony T. Papenfuss; Olga Kondrashova; Matthew J. Wakefield; Cassandra J. Vandenberg; Martin R. Stockler; Clare L. Scott; Paul M. Waring
err分享
err收藏
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial早期PSMA上调对恩扎卢胺±177Lu-PSMA-617治疗高危转移性去势抵抗性前列腺癌疗效的预测价值:随机II期ENZA-p试验的亚组研究
err2026-04-01
err0
PREAI
errEmmett, Louise; Swiha, Mina; Papa, Nathan; Subramaniam, Shalini; Crumbaker, Megan; Joshua, Anthony; Nguyen, Andrew; Weickhardt, Andrew; Lee, Sze-Ting; Ng, Siobhan; Francis, Roslyn; Goh, Jeffrey; Pattison, David; Pathmanandavel, Sarennya; Hope, Thomas; Ayati, Narjess; Hofman, Michael; Sandhu, Shahneen; Niu, Claire; Martin, Andrew; Thomas, Hayley; Stockler, Martin; Davis, Ian
err分享
err收藏
Curability of metastatic cancer: a survey of medical oncologists
err2026-01-22
err0
errOAAI
errSubramaniam, Shalini; Bui, Kim Tam; Stockler, Martin R.; Kiely, Belinda E.
err分享
err收藏
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)
err2025-12-19
err0
PREAI
errGargi Kothari; Kenneth J. O’Byrne; Chris Brown; Martin R. Stockler; Mariya Walker; Nicholas Hardcastle; Tomas Kron; Hien V. Le; Suzanne Kosmider; Laird Cameron; Louis Lao; Paul Mitchell; Shankar Siva
err分享
err收藏
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测
err2025-12-17
err0
errOAAI
errSoumyajit Roy; Yilun Sun; Maha Hussain; Kim N. Chi; Karim Fizazi; Ian D. Davis; Susan Halabi; Neeraj Agarwal; Simon Chowdhury; Bertrand Tombal; Scott C. Morgan; Shawn Malone; Pedro C. Barata; Michael Ong; Christopher J. D. Wallis; Alejandro Berlin; Umang Swami; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Jorge A. Garcia; Prateek Mendiratta; Jason R. Brown; Vinod V. Subhash; Martin R. Stockler; Hayley Thomas; Rana R. McKay; Eric J. Small; Neal D. Shore; Fred Saad; Christopher J. Sweeney; Daniel E. Spratt
err分享
err收藏
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer转移性激素敏感性前列腺癌早期多西他赛和恩扎卢amide目标试验模拟
err2025-11-05
err0
PREAI
errYu Yang Soon; Ian C. Marschner; I. Manjula Schou; Christopher J Sweeney; Ian D. Davis; Martin R. Stockler; Andrew J. Martin
err分享
err收藏
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseINTEGRATE合并的II/III期结果对进展后转换和胜者诅咒具有稳健性。
err2025-08-01
err0
errOAAI
errSoon, Yu Yang; Sjoquist, Katrin; Marschner, Ian C.; Schou, I. Manjula; Pavlakis, Nick; Goldstein, David; Shitara, Kohei; Stockler, Martin R.; Simes, John; Martin, Andrew J.
err分享
err收藏
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值:一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究
err2025-07-30
err0
PREAI
errLouise Emmett; Nathan Papa; Shalini Subramaniam; Megan Crumbaker; Andrew Nguyen; Anthony M Joshua; Shahneen Sandhu; Andrew Weickhardt; Sze-Ting Lee; Siobhan Ng; Roslyn J Francis; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Narjess Ayati; Claire Niu; Michael S Hofman; Andrew James Martin; Hayley Thomas; Ian D Davis; Martin R Stockler
err分享
err收藏
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)循环脂质面板PCPro与转移性激素敏感前列腺癌临床结局的关联:ENZAMET III期随机试验(ANZUP 1304)的事后分析
err2025-05-20
err0
PREAI
errH.-M. Lin; T. Scheinberg; N. Portman; R.M.N. Kim; R. Mellor; K. Huynh; A.N. Faulkner; N.A. Mellett; I.D. Davis; A. Martin; D. Sullivan; A. Joshua; M. McJannett; V. Subhash; S. Yip; A.A. Azad; I.C. Marschner; S.A. North; R.S. McDermott; K.N. Chi; M.R. Stockler; C.J. Sweeney; P.J. Meikle; L.G. Horvath
err分享
err收藏
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)Durvalumab,Tremelimumab和铂类化疗在EGFR突变阳性NSCLC中的应用开放标签2期试验 (illumate)
err2025-02-01
err0
errOAAI
errLee, Chee Khoon; Liao, Bin-Chi; Subramaniam, Shalini; Chiu, Chao-Hua; Mersiades, Antony; Ho, Chao-Chi; Brown, Chris; Lai, Chun-Liang; Hughes, Brett G. M.; Yang, Tsung-Ying; O'Byrne, Ken; Luo, Yung-Hung; Yip, Sonia; Ho, Ching-Liang; Bray, Victoria; Su, Wu-Chou; Moore, Melissa; Feng, Wei-Lien; Bai, Ya-Ying; Ford, Kate; Cummins, Michelle M.; Stockler, Martin R.; Solomon, Benjamin J.; John, Thomas; Yang, James Chih-Hsin
err分享
err收藏
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy
err2024-12-16
err0
errOAAI
errMellor, Rhiannon; Ardolino, Luke; Scheinberg, Tahlia; Fitzpatrick, Michael; Lin, Hui-Ming; Bonnitcha, Paul; Sullivan, David; Meikle, Peter J.; Stockler, Martin R.; Moujaber, Tania; Joshua, Anthony; Horvath, Lisa
err分享
err收藏
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
err2024-09-17
err1
errOAAI
errSharifi, Nima; Diaz, Robert; Lin, Hui-Ming; Roberts, Evan; Horvath, Lisa G.; Martin, Andrew; Stockler, Martin R.; Yip, Sonia; Subhash, Vinod V.; Portman, Neil; Davis, Ian D.; Sweeney, Christopher J.
err分享
err收藏
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)CCTG BR.31:一项关于完全切除的非小细胞肺癌(NSCLC)辅助治疗中 durvalumab 的全球性、双盲、安慰剂对照、随机III期研究
err2024-09-01
err6
PREAI
errGoss, G.; Darling, G. E.; Westeel, V.; Nakagawa, K.; Massuti Sureda, B.; Perrone, F.; McLachlan, S-A.; Kang, J. H.; Wu, Y-L.; Dingemans, A-M. C.; Dziadziuszko, R.; Okada, M.; Greillier, L.; Audigier-Valette, C.; Sugawara, S.; Nadal, E.; Catino, A.; Stockler, M. R.; Ding, K.; O'Callaghan, C.
err分享
err收藏
Challenges of estimating treatment effects after a positive interim analysis
err2024-09-01
err0
PREAI
errSoon, Yu Yang; Marschner, Ian C.; Schou, Manjula; Sweeney, Christopher J.; Davis, Ian D.; Stockler, Martin R.; Martin, Andrew J.
err分享
err收藏
Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)脂质生物标志物PCPro与临床结局的关联:ENZAMET试验(ANZUP 1304)
err2024-09-01
err0
PREAI
errHorvath, L. G.; Lin, H-M.; Davis, I. D.; Martin, A.; Scheinberg, T.; Meikle, P.; Joshua, A.; Mcjannett, M.; Subhash, V.; Yip, S.; North, S.; McDermott, R. S.; Chi, K. N.; Stockler, M. R.; Sweeney, C.
err分享
err收藏
Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)ENZAMET(ANZUP 1304)研究中,转移性激素敏感性前列腺癌(mHSPC)高容量亚组内的临床预后因素
err2024-09-01
err0
PREAI
errHamid, A. A.; Thomas, H.; Martin, A.; Soon, Y. Y.; Horvath, L. G.; Zielinski, R.; Thomson, A.; Tan, H.; Sandhu, S. K.; Reaume, M. N.; Pook, D. W.; Parnis, F.; McDermott, R. S.; Lawrence, N.; Frydenberg, M.; Chi, K. N.; Stockler, M. R.; Davis, I. D.; Sweeney, C.
err分享
err收藏